Next Article in Journal
Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications
Previous Article in Journal
Emerging Roles of Ephexins in Physiology and Disease
Previous Article in Special Issue
NUP214 in Leukemia: It’s More than Transport
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Cells 2019, 8(2), 88;

Hutchinson-Gilford Progeria Syndrome—Current Status and Prospects for Gene Therapy Treatment

Laboratory of Nuclear Proteins, Faculty of Biotechnology, University of Wroclaw, Fryderyka Joliot-Curie 14a, 50-383 Wroclaw, Poland
Author to whom correspondence should be addressed.
Joint first author.
Received: 1 December 2018 / Revised: 18 January 2019 / Accepted: 19 January 2019 / Published: 25 January 2019
(This article belongs to the Special Issue Nuclear Transport in Ageing and Diseases)
Full-Text   |   PDF [915 KB, uploaded 25 January 2019]   |  
  |   Review Reports


Hutchinson-Gilford progeria syndrome (HGPS) is one of the most severe disorders among laminopathies—a heterogeneous group of genetic diseases with a molecular background based on mutations in the LMNA gene and genes coding for interacting proteins. HGPS is characterized by the presence of aging-associated symptoms, including lack of subcutaneous fat, alopecia, swollen veins, growth retardation, age spots, joint contractures, osteoporosis, cardiovascular pathology, and death due to heart attacks and strokes in childhood. LMNA codes for two major, alternatively spliced transcripts, give rise to lamin A and lamin C proteins. Mutations in the LMNA gene alone, depending on the nature and location, may result in the expression of abnormal protein or loss of protein expression and cause at least 11 disease phenotypes, differing in severity and affected tissue. LMNA gene-related HGPS is caused by a single mutation in the LMNA gene in exon 11. The mutation c.1824C > T results in activation of the cryptic donor splice site, which leads to the synthesis of progerin protein lacking 50 amino acids. The accumulation of progerin is the reason for appearance of the phenotype. In this review, we discuss current knowledge on the molecular mechanisms underlying the development of HGPS and provide a critical analysis of current research trends in this field. We also discuss the mouse models available so far, the current status of treatment of the disease, and future prospects for the development of efficient therapies, including gene therapy for HGPS. View Full-Text
Keywords: HGPS; laminopathy; lamin A/C; progerin; gene therapy; miR9 HGPS; laminopathy; lamin A/C; progerin; gene therapy; miR9

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Piekarowicz, K.; Machowska, M.; Dzianisava, V.; Rzepecki, R. Hutchinson-Gilford Progeria Syndrome—Current Status and Prospects for Gene Therapy Treatment. Cells 2019, 8, 88.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top